NASDAQ:MSONMisonix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Misonix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.85 -0.11 (-0.79 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$13.61Now: $13.85▼$14.4250-Day Range$10.09MA: $11.95▼$13.9352-Week Range$6.71Now: $13.85▼$27.54Volume111,985 shsAverage Volume105,409 shsMarket Capitalization$240.44 millionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMisonix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.67, Misonix has a potential upside of 27.6% from its current price of $13.85.Amount of Analyst CoverageMisonix has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesMisonix has received 118 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMisonix has received 140 “underperform” votes. (Add your “underperform” vote.)Community SentimentMisonix has received 54.26% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Misonix and other stocks. Vote “Outperform” if you believe MSON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MSON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMisonix does not currently pay a dividend.Dividend GrowthMisonix does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Misonix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $98,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 32.81% of the stock of Misonix is held by insiders.Percentage Held by Institutions37.63% of the stock of Misonix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Misonix is -18.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Misonix is -18.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMisonix has a P/B Ratio of 6.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.96 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Laboratory apparatus & furniture Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:MSON Previous Symbol CUSIPN/A CIK880432 Webwww.misonix.com Phone631-694-9555Debt Debt-to-Equity Ratio0.26 Current Ratio4.91 Quick Ratio4.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$38.85 million Price / Sales6.19 Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book6.16Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,390,000.00 Net Margins-19.18% Return on Equity-9.13% Return on Assets-6.69%Miscellaneous Employees118 Outstanding Shares17,360,000Market Cap$240.44 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:MSON Rates by TradingView Receive MSON News and Ratings via Email Sign-up to receive the latest news and ratings for MSON and its competitors with MarketBeat's FREE daily newsletter. Misonix (NASDAQ:MSON) Frequently Asked Questions How has Misonix's stock been impacted by COVID-19 (Coronavirus)? Misonix's stock was trading at $10.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MSON stock has increased by 29.7% and is now trading at $13.85. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Misonix? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Misonix. When is Misonix's next earnings date? Misonix is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Misonix. How were Misonix's earnings last quarter? Misonix, Inc. (NASDAQ:MSON) posted its quarterly earnings results on Monday, May, 11th. The medical equipment provider reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.04. The medical equipment provider earned $17.90 million during the quarter. Misonix had a negative return on equity of 9.13% and a negative net margin of 19.18%. View Misonix's earnings history. What price target have analysts set for MSON? 2 analysts have issued 1-year price objectives for Misonix's shares. Their forecasts range from $13.00 to $22.00. On average, they expect Misonix's share price to reach $17.67 in the next year. This suggests a possible upside of 27.6% from the stock's current price. View analysts' price targets for Misonix. Has Misonix been receiving favorable news coverage? News headlines about MSON stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Misonix earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutMisonix. Who are some of Misonix's key competitors? Some companies that are related to Misonix include Ceres Power (CWR), 3D Systems (DDD), Inseego (INSG), Infinera (INFN), SMA Solar Technology (S92), Anterix (ATEX), QAD (QADA), Gree,Inc. (GREZF), FIH MOBILE LTD/ADR (FXCNY), Celestica (CLS), Upland Software (UPLD), Simulations Plus (SLP), Domo (DOMO), Nlight (LASR) and Axcelis Technologies (ACLS). View all competitors. What other stocks do shareholders of Misonix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Misonix investors own include Edap Tms (EDAP), Canopy Growth (CGC), Varian Medical Systems (VAR), Second Sight Medical Products (EYES), Sociedad Quimica y Minera de Chile (SQM), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY) and AbbVie (ABBV). Who are Misonix's key executives? Misonix's management team includes the following people: Mr. Stavros George Vizirgianakis, Pres, CEO & Director (Age 49)Mr. Joseph P. Dwyer, CFO, Treasurer & Sec. (Age 63)Mr. Robert Scott Ludecker, Sr. VP of Global Sales & Marketing (Age 52)Ms. Sharon W. Klugewicz, Chief Operating Officer (Age 51)Mr. John J. Salerno, VP of Quality and Regulatory Affairs & Chief Compliance Officer (Age 64) What is Misonix's stock symbol? Misonix trades on the NASDAQ under the ticker symbol "MSON." Who are Misonix's major shareholders? Misonix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.74%), Juniper Investment Company LLC (2.28%), Soleus Capital Management L.P. (1.37%), Geode Capital Management LLC (0.97%), State Street Corp (0.84%) and Millrace Asset Group Inc. (0.37%). Company insiders that own Misonix stock include Christopher H Wright, Joseph J Brennan, Joseph P Dwyer, Sharon W Klugewicz and Stavros G Vizirgianakis. View institutional ownership trends for Misonix. Which major investors are selling Misonix stock? MSON stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, and Rathbone Brothers plc. View insider buying and selling activity for Misonix. Which major investors are buying Misonix stock? MSON stock was bought by a variety of institutional investors in the last quarter, including Juniper Investment Company LLC, Millrace Asset Group Inc., Soleus Capital Management L.P., BlackRock Inc., Geode Capital Management LLC, Two Sigma Investments LP, Mesirow Financial Investment Management Inc., and State Street Corp. Company insiders that have bought Misonix stock in the last two years include Joseph P Dwyer, Sharon W Klugewicz, and Stavros G Vizirgianakis. View insider buying and selling activity for Misonix. How do I buy shares of Misonix? Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Misonix's stock price today? One share of MSON stock can currently be purchased for approximately $13.85. How big of a company is Misonix? Misonix has a market capitalization of $240.44 million and generates $38.85 million in revenue each year. Misonix employs 118 workers across the globe. What is Misonix's official website? The official website for Misonix is www.misonix.com. How can I contact Misonix? Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at 631-694-9555. This page was last updated on 6/5/2020 by MarketBeat.com Staff
